{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-045073","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2025-05-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.103804+00:00","generated_at":"2026-05-22T11:19:25.942200+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Protagonist Q1 EPS -$0.19; rusfertide Phase 3 positive, ASCO plenary June 1","bullets":["Cash $697.9M (up from $559.2M Dec 2024); net loss $11.7M (-$0.19/sh) vs income $207.3M in Q1 2024.","Rusfertide Phase 3 VERIFY in PV met primary endpoint (p<0.0001) and all 4 key secondaries; ASCO plenary June 1, conf call June 2.","Icotrokinra Phase 3 ICONIC-LEAD data presented at AAD and WCPD; Phase 2b ANTHEM-UC positive, full data later in 2025.","Revenue $28.3M includes $22.8M rusfertide milestone recognition; vs $255M Q1 2024 with Takeda upfront.","Pipeline: oral IL-17 antagonist PN-881 to enter clinic in 2025; cash runway through at least end of 2028."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-045073","json":"https://secwatch.observer/filing/0001104659-25-045073.json","markdown":"https://secwatch.observer/filing/0001104659-25-045073.md","text":"https://secwatch.observer/filing/0001104659-25-045073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925045073/0001104659-25-045073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465925045073/tm2514117d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T11:19:25.942200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}